Key facts
- This page summarizes Bain Capital Life Sciences Investors, LLC's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Dec 2024, 17:05.
Bain Capital Life Sciences Investors, LLC - 13 Dec 2024 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NAMS
- Reported as of
- 13 Dec 2024
- Net transaction value
- +$39,999,835
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2024, 17:05:48 UTC
- Prior SEC filing
- 14 Feb 2024
- Next SEC filing
- 13 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- See signatures included in Exhibit 99.1
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Bain Capital Life Sciences Investors, LLC filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 17 Dec 2024.
Change
- Previous filing in this sequence was filed on 14 Feb 2024.
- Current net transaction value: +$39,999,835.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NAMS
transaction
Derivative
Pre-Funded Warrant (right to buy)
Purchase
- Transaction value
- $39,999,835
- Shares
- +1,632,653
- Change %
- Price
- $24.50
- Shares after
- 1,632,653
- Date
- 13 Dec 2024
- Ownership
- See footnotes
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,632,653
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F4, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Bain Capital Life Sciences Investors, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
Represents a pre-funded warrant to purchase 1,257,141 Ordinary Shares and a pre-funded warrant to purchase 375,512 Ordinary Shares, purchased by Bain Capital Life Sciences Opportunities III, LP ("BCLS Fund III Opportunities") and BCLS II Equity Opportunities, LP ("BCLS Fund II Opportunities"), respectively, in an underwritten public offering.
Footnote F2
The pre-funded warrants cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of Ordinary Shares then outstanding immediately following such exercise.
Footnote F3
The pre-funded warrants do not expire.
Footnote F4
Bain Capital Life Sciences III General Partner, LLC ("BCLS III GP") is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS III"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC ("BCLS Fund III Opportunities GP"), which is the general partner of BCLS Fund III Opportunities. As a result, each of BCLS III GP and BCLS III may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Opportunities. Each of BCLS III GP and BCLS III disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F5
Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), which is the manager of BCLS II Equity Opportunities GP, LLC, which is the general partner of BCLS Fund II Opportunities. As a result, each of BCLSI II and BCLS Fund II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II Opportunities. Each of BCLSI II and BCLS Fund II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F6
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of each of BCLS III GP and BCLSI II. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by each of BCLS Fund III Opportunities and BCLS Fund II Opportunities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.